600% Kurspotential YM Biosciences 911799

YM Biosciences announces FDA clearance for two Phase II nimotuzumab trials
YM BioSciences announced that the FDA has advised the company that it may now enroll patients at U.S. clinical sites into two ongoing randomized, double-blind Phase II trials of its lead product, nimotuzumab. One of the two trials is in non-small-cell lung cancer patients who are ineligible for curative treatment and being treated palliatively and the other in patients with brain metastases from NSCLC. Current NSCLC palliative treatment and treatment for brain metastases is radiation alone. :theflyonthewall.com  

 

"YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA (YMI) 1.65 : Co announces that the FDA has advised the Company that it may now enroll patients at US clinical sites into two ongoing randomized, double-blind Phase II trials of its lead product, nimotuzumab. One of the two trials is in non-small-cell lung cancer patients who are ineligible for curative treatment and being treated palliatively and the other in patients with brain metastases from NSCLC. Current NSCLC palliative treatment and treatment for brain metastases is radiation alone."

Quelle: Yahoo, January 26, 2010, 7:30 am EST
http://finance.yahoo.com/news/...prnews-4173624457.html?x=0&.v=12  

dann kanns aufwärts gehen. dasselbe phänomen haben wir gestern Keryx gesehen.
Beides Highflyer....
Phase 2 News sind nun mal nicht so der Renner, aber die phase 3 news kommen ganz bestimmt.
:-)  

eine kruze Auflistung des Produkts "Nimotuzumab"

2 x Phase II  (nicht-kleinzelliger Lungenkrebs, Magenkrebs)

3 x Phase III (Kopf & Nackenkrebs, Hirntumore Kinder & Erwachsene, Bauchspeicheldrüsenkrebs)

...natürlich nur ein kleiner Auszug. Schaut man sich allerdings die komplette Pipeline an, zeigt sich ein großes Potenzial.

http://www.ymbiosciences.com/products/clinical_trials.php

Hier werden wir in der nächsten Zeit einen ordentlichen Datenflut bekommen.  

natürlich müsste es heissen... "eine ordentliche datenflut"
big sorry, war etwas in eile :)  

mir erschließt sich das nicht.
shorties?  

man muss nur ein wenig geduldig sein :)

lg  

hoffen wir auf weitere gute news in bälde

es stehen genügend entscheidungen an.  

 

aber zulassungen machen die kurse  

kurs konsolidiert noch....
NOCH  

Attention Business Editors

YM BioSciences granted two US patents for AeroLEF(R)

          §    - Additional AeroLEF patents granted in Europe, China and other
territories -

          §    MISSISSAUGA, ON, Feb. 10 /CNW/ - YM BioSciences Inc. (NYSE Amex: YMI,
TSX:YM), announced that it has been granted two additional patents in the US
for AeroLEF(R), the Company's proprietary, inhaled-delivery composition of
free and liposome-encapsulated fentanyl in development for the treatment of
moderate to severe acute pain. US patent numbers 7,648,981 and 7,648,982
extend the life of YM's AeroLEF patent estate in the US to 2024. The Company
also announced that AeroLEF's patent estate has expanded to include other
territories with the issuance of European patent number 1,603,533 and several
patent allowances in China, India, Mexico and other territories.
          §    "These patents strengthen and extend the patent protection for AeroLEF in
the US, and also expand the global market for this unique and potentially
first in class product," said David Allan, CEO of YM BioSciences. "The
scientific pedigree and unique advantages of this product have been
established and its safety and efficacy have been demonstrated in numerous
clinical trials. AeroLEF has met all endpoints in each of its trials including
a randomized Phase II trial and is currently being prepared for late-stage
development internationally."
          §    US patent number 7,648,981 protects the self-medicating method of pain
management in which the pain sufferer inhales a formulation comprising free
and liposomal fentanyl in a dose ratio that provides rapid onset and sustained
relief from pain without attendant toxicity. Also claimed is a breath-actuated
device for delivering the fentanyl formulation.
          §    US patent number 7,648,982 similarly covers a pain relief method and
device that delivers fentanyl formulations defined according to the particle
sizes and unit doses effective to manage pain by the route of pulmonary
delivery. European patent number 1,603,533 and other recently allowed patents'
coverage is similar in scope to the recently issued US patents.
          §    AeroLEF's current patent estate in the US consists of three issued
patents and two pending patents.

          §    About AeroLEF(R)

          §    AeroLEF(TM) is a unique, inhaled-delivery composition of free and
liposome-encapsulated fentanyl in development for the treatment of moderate to
severe pain, including cancer pain. In contrast to fixed-dose approaches to
opioid delivery, where a significant titration period is often required to
determine the suitable dose for the patient, AeroLEF is being developed as a
non-invasive delivery system designed to enable patients to self-titrate.
Using AeroLEF, patients can identify and select a personalized dose for each
pain episode, achieving both rapid onset and extended duration of analgesia.

          §    About YM BioSciences

          §    YM BioSciences Inc. is a life sciences product development. Together with
the products from YM Australia (formerly Cytopia Limited), the Company is
currently developing four late-stage products: nimotuzumab, an EGFR-targeting
Affinity-Optimized Antibody(TM); CYT 387, a JAK 1/2 small molecule inhibitor,
CYT 997, a potent, vascular disrupting agent and AeroLEF(R), a proprietary,
inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM
has proven regulatory and clinical trial expertise and a diversified business
model designed to reduce risk while advancing clinical products toward
international approval, marketing and commercialization.
          §    Nimotuzumab is a humanized monoclonal antibody in development worldwide,
targeting multiple tumor types primarily in combination with radiation and
chemoradiation. It is importantly differentiated from all other currently
marketed EGFR-targeting agents due to its remarkably benign side-effect
profile. Nimotuzumab's anti-tumor activity has led to its approval for
marketing in 23 countries. In more than 9,000 patients reported as having been
treated with nimotuzumab worldwide to date, Grade IV incidents of radiation
dermatitis and incidents of severe rash have been only rarely observed and
reports of the other severe side-effects that are typical of EGFR-targeting
molecules have been equally rare. Nimotuzumab is licensed to YM's
majority-owned, Canadian subsidiary, CIMYM BioSciences Inc., by CIMAB S.A.,
and was developed at the Center of Molecular Immunology. The products
discovered by YM's recently acquired Australian subsidiary include the JAK 1/2
inhibitor CYT387, and the novel VDA molecule CYT997. Both were discovered
internally at Cytopia based on research led by Dr Andrew Wilks who identified
the JAK 1/2 kinase enzymes. Both products are currently in clinical
development. YM is developing AeroLEF for the treatment of moderate to severe
acute pain. The product is differentiated from other approaches using opioids
because patients are able to individually control the analgesia required for
their differing intensities of pain.

          §    This press release may contain forward-looking statements, which reflect
the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may cause
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, but are not limited to,
changing market conditions, the successful and timely completion of clinical
studies, the establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to time in the
Company's ongoing quarterly and annual reporting. Certain of the assumptions
made in preparing forward-looking statements include but are not limited to
the following: that nimotuzumab will continue to demonstrate a competitive
safety profile in ongoing and future clinical trials; that JAK 1/2 and the VDA
molecule will generate positive efficacy and safety data in future clinical
trials; AeroLEF(R) will continue to generate positive efficacy and safety data
in future clinical trials; that and that YM and its various partners will
complete their respective clinical trials within the timelines communicated in
this release. We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.  

11.02.2010 13:33
YM BioSciences presents CYT387 and CYT997 data at international cancer conference



MISSISSAUGA, ON, Feb. 11 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM), is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.

The CYT387 poster, "A novel, potent and selective dual inhibitor of JAK1 and JAK2 for treatment of myeloproliferative neoplasms and cancer" was presented Thursday, February 11th at 7:30 pm AEDT.

Dr. Chris Burns, Research Director at YM Australia, presented the poster on CYT387 which is currently being investigated in a Phase I/II clinical trial for myelofibrosis at Mayo Clinic, in Rochester, MN. The poster describes important preclinical data obtained for CYT387 including comparison to other reported JAK inhibitors. In a number of different assays CYT387 is shown to be a potent and selective JAK1/JAK2 inhibitor, with a promising activity profile for treatment of myeloproliferative neoplasms (MPNs) and other diseases.

The CYT997 poster, "Vascular targeting and anti-tumour efficacy of orally administered CYT997 in combination with cisplatin in a DLD-1 human colon adenocarcinoma xenograft model." is being presented Friday, February 12th at 8:00pm AEDT (4:00am EST).

Dr. Andrew Powell, Preclinical Project Manager at YM Australia, will present the poster on the vascular disrupting agent, CYT997, which is currently in a Phase II trial for glioblastoma multiforme, a brain cancer with very poor prognosis, despite multimodal treatment. The poster outlines data from preclinical studies demonstrating the profound vascular disrupting effects achieved with CYT997 through repeated oral daily dosing. In addition, data will be presented showing that a combination of the conventional chemotherapeutic agent cisplatin with daily dosing of CYT997 leads to an improved response in a model of colon cancer.

Additional information on the Lorne Cancer Conference is available at http://www.lornecancer.org/. Abstracts for both posters will be posted at the time of presentation at http://www.ymbiosciences.com/.

About YM BioSciences

YM BioSciences Inc. is a life sciences product development. Together with the products from YM Australia (formerly Cytopia Limited), the Company is currently developing four late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM); CYT 387, a JAK 1/2 small molecule inhibitor, CYT 997, a potent, vascular disrupting agent and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is importantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in 23 countries. In more than 9,000 patients reported as having been treated with nimotuzumab worldwide to date, Grade IV incidents of radiation dermatitis and incidents of severe rash have been only rarely observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been equally rare. Nimotuzumab is licensed to YM's majority-owned, Canadian subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. The products discovered by YM's recently acquired Australian subsidiary, YM Australia (formerly Cytopia Limited), include the JAK 1/2 inhibitor CYT387, and the novel VDA molecule CYT997. Both were discovered internally at Cytopia based on research led by Dr Andrew Wilks who identified the JAK 1/2 kinase enzymes. Both products are currently in clinical development. YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using opioids because patients are able to individually control the analgesia required for their differing intensities of pain. AeroLEF has met all endpoints in each of its trials including a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that JAK 1/2 and the VDA molecule will generate positive efficacy and safety data in future clinical trials; AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; that and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

YM BioSciences Inc.

CONTACT: Enquiries: James Smith, the Equicom Group Inc., Tel. (416)
815-0700 x 229, Email: jsmith@equicomgroup.com; Thomas Fechtner, the Trout
Group LLC, Tel. (646) 378-2931, Email: tfechtner@troutgroup.com  

warum so schweigsam
war wohl nichts mit der Puscherei, dieser kleine Ausrutscher heute nach unten.
Der Anfang vom Ende?  

bringt doch eh nichts
ich glaub es kommen schon bald wieder news
war eben ne kapitalerhöhung, das ist ok

und das so ganz ohne meine pusherei?!?! wie geht das denn...
hier brauchts keine pusherei!!!! wir sind eh bald über 2 dollar.

hier kommt bald eine datenflut, eine positive...


:-)

dann auch mal ne Zulassung! Wieviele Produkte sind im Moment in der Phase III?  

los kriege!

Wo bleibt den Umsatz, vor 2 -3 Jahren war hier die Hölle los....

Könnte ich meine Shares auch in Übersee verkaufen? Bin bei Flatex....ok Hot-Line anrufen habe ich kein Bock

Wer kann mir was dazu sagen?
Danke  

das sehe ich auch so Die haben sehr viele Phase 3 und 2 Produkte. Die Chance ist also sehr hoch, dass wir bald eine vervielfachung des Kurses sehen:)  

Darauf warte ich seit 2007!

Bin damals bei 1 € eingestiegen als der Kurs von ca. 3 € runter kam....

Würde mich echt freuen wenn wir die 2€ Marke bald sehen könnten :-) (dann könnte ich mich mit einer zweistellige Durchschnitt Rendite zufrieden geben !(von 2007 bis 2011 :)  

das denke ich auf jeden Fall. Und zwar sind zur Zeit biotech Aktien wieder mal heiß begehrt und diese Firma hat auf jeden Fall genug in der Pipeline, damit etwas zugelassen wird oder die Phase 2 Medikamente in Phase 3 übertreten. Leider ist es meistens so, dass man einige Zeit warten muss aber ich denke du wirst bald sicherlich eine positive Überraschung erleben. Also bleib drin lg  

im Pretrade  

kapitalerhöhung waren.
wenn jetzt noch die erwartete richtig gute nachricht kommt und wir den widerstand bei 1,90 überwinden kann es richtig gut nach oben gehen.
bin gespannt